From the trials that incorporated a MICON protocol, one trial (Lutz et al. 2016) reported a 23% increase on CD34+/KDR+ EPCs in a normal glucose tolerance group, while no changes were observed in the impaired glucose tolerance and T2DM groups. This evidence concerns the gene CD34 and type 2 diabetes mellitus.